PS—01Out of stock · 2026-07-13
Weight loss
Retatrutide
LY3437943
Activates GLP-1, GIP and glucagon receptors simultaneously to suppress appetite and raise energy expenditure.
Vetted partner · affiliate marketplace
Research first. Purchase second.
PeptideStat does not manufacture, sell or fulfill products. We review the evidence, the vendor's public COAs and the questions buyers should ask—then link out to our current research-marketplace partner.
Partner code / verify at checkout
PEPTIDESDECatalog53 audited
Intended useResearch only
We may earn a commission at no additional cost to you. Current savings, availability and lot documentation can change; verify all three on the destination site.
01
Check the evidence
Read the compound guide and confirm whether the evidence is human, animal or preclinical.
02
Open the lot COA
Match the lot number, testing method and date to the exact listing you are considering.
03
Verify at checkout
Confirm the current code, total price, shipping terms and research-use acknowledgment.
Evidence-linked catalog index
Follow the data to the listing.
Approval status describes the compound in the evidence database—not the partner's research-use product. A research listing is never a prescription medicine.
PS—02Approved
Weight loss
Tirzepatide
LY3298176, Mounjaro, Zepbound
Activates GLP-1 and GIP receptors to improve glycemic control and reduce appetite + body weight.
PS—03Approved
Weight loss
Semaglutide
Ozempic, Wegovy, Rybelsus
Mimics the incretin GLP-1, slowing gastric emptying and reducing appetite while improving insulin secretion.
PS—04Investigational
Weight loss
Cagrilintide
AM833
Long-acting amylin analog that slows gastric emptying and reinforces satiety; studied in combination with semaglutide (CagriSema).
PS—05Research only
Healing & recovery
BPC-157
Body Protection Compound-157
Derived from human gastric juice. Animal models suggest effects on angiogenesis, tendon healing and GI repair; human clinical data is very limited.
PS—06Research only
Healing & recovery
TB-500
Thymosin Beta-4 fragment
Synthetic fragment of thymosin β4 studied in animal models for cell migration, angiogenesis and tissue repair. No approved human indication.
PS—07Research only
Growth hormone
Ipamorelin
NNC 26-0161
Selectively stimulates pituitary growth hormone release without significant cortisol or prolactin elevation seen with older GHRPs.
PS—08Out of stock · 2026-07-13
Growth hormone
CJC-1295
DAC:GRF
Long-acting growth-hormone-releasing hormone analog. The DAC variant binds serum albumin to extend half-life and sustain GH/IGF-1 elevation.
PS—09Approved
Growth hormone
Tesamorelin
Egrifta
Stabilized GHRH analog. Approved for reduction of excess visceral abdominal fat in HIV-associated lipodystrophy.
PS—10Research only
Longevity
GHK-Cu
Copper tripeptide-1
Naturally occurring tripeptide bound to copper. Studied for wound healing, skin remodeling and gene-expression effects related to tissue repair.
PS—11Research only
Cognitive
Selank
TP-7
Russian-developed analog of tuftsin marketed (in Russia) as an anxiolytic. Mechanism involves modulation of GABA and stress-response pathways.
PS—12Research only
Cognitive
Semax
ACTH(4-10) analog
Heptapeptide derived from ACTH(4-10). Russian neuropeptide studied for nootropic and neuroprotective effects, partly via BDNF upregulation.
PS—13Investigational
Healing & recovery
VIP (Vasoactive Intestinal Peptide)
Aviptadil
VIP activates VPAC1 and VPAC2 receptors, raising intracellular cyclic AMP to drive vasodilation, smooth-muscle relaxation and immune modulation.
PS—14Out of stock · 2026-07-13
Longevity
Pinealon
Glu-Asp-Arg tripeptide
Pinealon is proposed to penetrate cells and the blood-brain barrier and bind directly to DNA promoter regions and histone proteins, shifting expression of antioxidant and neuroprotective genes rather than acting through a classical membrane receptor.
Read this first
PeptideStat is educational, not medical advice. Many compounds we cover are investigational or research-only and are not approved for human use. Partner links may earn us a commission without changing your price or our editorial conclusions.
Full disclosure →